Horizon Pharma aborts key Actimmune trial; shares plunge

(Reuters) – Horizon Pharma Plc’s shares tumbled 18 percent after the company ended a late-stage trial that was testing its drug, Actimmune, as a treatment for a rare neuromuscular disorder that has no approved medicines. Actimmune failed to demonstrate a statistically significant benefit over a placebo in patients with Friedreich’s ataxia (FA) on a scale used to measure progression of the disease, the company said. The drug is already approved by the U.S. Food and Drug Administration for use in two rare, genetic conditions – chronic granulomatous disease and severe, malignant osteopetrosis.
Go to Source

Dead brother’s vest, bracelet, coffee pot: what refugees take when they flee

By Emma Batha LONDON (Thomson Reuters Foundation) – When Syrian refugee Zakaria Alssayadi fled his village he grabbed his passport, money and the plain white vest his beloved brother was wearing the day he died of cancer. Fellow refugee Amal Tayyawi took a bracelet given by her sister, Anas Humidy picked up his poetry, Kawther Jahwani her coffee pot and five-year-old Nizar Rastnawi his Spiderman costume. These treasured items and the stories behind them feature in a film project by the charity International Medical Corps which aims to put a human face on the refugee crisis. …
Go to Source

1 7 8 9 10 11